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ABSTRACT
The p53 tumor suppressor protein, often termed
guardian of the genome, integrates diverse physio-
logical signals in mammalian cells. In response to
stress signals, perhaps the best studied of which is
the response to DNA damage, p53 becomes func-
tionally active and triggers either a transient cell
cycle arrest, cell death (apoptosis) or permanent cell
cycle arrest (cellular senescence). Both apoptosis
and cellular senescence are potent tumor suppres-
sor mechanisms that irreversibly prevent damaged
cells from undergoing neoplastic transformation.
However, both processes can also deplete renew-
able tissues of proliferation-competent progenitor
or stem cells. Such depletion, in turn, can compro-
mise the structure and function of tissues, which
is a hallmark of aging. Moreover, whereas apoptotic
cells are by definition eliminated from tissues,
senescent cells can persist, acquire altered func-
tions, and thus alter tissue microenvironments in
ways that can promote both cancer and aging
phenotypes. Recent evidence suggests that
increased p53 activity can, at least under some
circumstances, promote organismal aging. Here, we
discuss the role of p53 as a key regulator of the DNA
damage responses, and discuss how p53 integrates
the outcome of the DNA damage response to
optimally balance tumor suppression and longevity.
INTRODUCTION
Longevity assuranceand tumor suppression
Cancer is a potentially lethal disease that poses a major
challenge to longevity in organisms with renewable tissues.
Cancers, or malignant tumors, contain cells that have
acquired several aberrant properties, often by somatic
mutation or epigenetic changes in gene expression. These
properties include uncontrolled proliferation, resistance to
cell death signals, inappropriate migratory and invasive
capability, and the capacity to alter the tissue
microenvironment to promote angiogenesis and evasion
of immune surveillance (1). A number of mammalian
genes function to prevent the development of cancer, some
of which are directly implicated in longevity assurance.
One such longevity assurance gene is TP53, which encodes
the tumor suppressor protein p53. p53 promotes longevity
by reducing somatic mutations and/or the survival or
proliferation of mutant cells, thereby reducing the
occurrence of cancer (2,3). Interestingly, however, recent
ﬁndings suggest that too much of a good thing, even
increased tumor suppression by p53, can have deleterious
eﬀects and promote selected aspects of the aging process
(4–6). These ﬁndings suggest there is a tight balance
between tumor suppression and long-term cell prolifera-
tive potential, which is essential for the longevity of
organisms, such as mammals, with renewable tissues.
DNA damage, stemcells and differentiated somatic tissues
Cancer is a major age-related disease in mice, humans
and many other mammals (7). In the absence of cancer,
aging is mostly characterized by tissue atrophy and
degeneration (8).
Most mammalian tissues can be described as being
comprised of two major cellular components: stem or
progenitor cells, which are responsible for regenerative
capacity or repair after injury, and diﬀerentiated somatic
cells, responsible for adult stem cell support and special-
ized tissue/organ functions. Based on this classiﬁcation,
two major mechanisms can account for tissue degenera-
tion associated with age: loss of stem cell pool division
potential (loss of regenerative capacity) and loss of
diﬀerentiated somatic cell function, which directly leads
to loss of organ function. Loss of diﬀerentiated somatic
cell function can additionally indirectly aﬀect adult stem
and progenitor cells by altering the tissue microenviron-
ment that is essential for stem cell support (the stem cell
niche). In general, loss of stem cell pool division potential
can occur through multiple mechanisms including stem
cell senescence, death or dysfunction of the niche. One
speciﬁc mechanism that can account for the loss of both
stem cell and diﬀerentiated somatic cell function is the
gradual accumulation of persistent DNA damage.
Persistent DNA damage and its erroneous resolution
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tions (12), both of which increase with age; both also have
been proposed to contribute to the loss of stem and
diﬀerentiated somatic cell function with age (13,14). DNA
damage accumulation in stem cells has been detected in
mice and clearly contributes to the attrition of stem cell
division potential during aging (15). Thus, it is likely that
DNA damage contributes to aging by limiting stem cell
division potential and by also interfering with somatic
tissue functions, including stem cell niches.
How does a loss of division potential result from DNA
damage? The answer lies in the signaling networks that
link lesions in the DNA to the activation of DNA damage
checkpoints, which in turn activate eﬀectors of critical cell
fate decisions. Interestingly, most regulators of the DNA
damage response channel the damage signals through the
well-known tumor suppressor protein, p53. Here, we
discuss how DNA damage activates p53 and how this
single protein integrates the outcome of the DNA damage
response to optimally balance tumor suppression and
longevity.
P53 AND DNA DAMAGE
p53:thequintessential tumor suppressor
p53 (Tumor protein p53, TP53, Li-Fraumeni syndrome 1)
has been studied for nearly three decades, and is best
known for its potent ability to suppress malignant
tumorigenesis. Only recently has it been appreciated that
p53 belongs to the ever-growing class of longevity
assurance genes. The activities of genes in this family,
mostly studied in lower organisms such as fruit ﬂies and
nematodes, ensure organismal longevity (3). p53 certainly
promotes long life by reducing the risk of cancer, a major
age-related disease. In addition, recent evidence suggests
p53 can stimulate the expression of genes that reduce
oxidative stress (16–18). Because oxidative damage is
generally believed to be an important contributor to both
the hyperproliferative age-related cancer and degenerative
changes of aging (19,20), p53 may therefore also promote
longevity by reducing oxidative stress. However, as
discussed below, p53 also plays a crucial role in
determining cell fate, and some cell fate decisions can
lead to aging phenotypes in aﬀected tissues. Thus, p53
might have both beneﬁcial and deleterious eﬀects,
depending on the physiological context.
Mutations in p53 reduce the ﬁdelity of genome
maintenance. Genomic instability is a major cause of
cancer and a hallmark of tumor progression; thus, the
longevity of both humans and mice with germline
deﬁciencies in p53 is curtailed by cancer (21,22). While it
is clear that p53 suppresses cancer, there is no single
mechanism by which this multifaceted protein suppresses
malignant transformation. p53 lies at the hub of complex
signaling networks that can integrate a multitude of
potentially oncogenic stress signals including, but not
limited to, oxidative stress (23), supraphysiological mito-
genic signals or activated oncogenes (24–26), metabolic
alterations (16,27) and DNA damage and repair, the focus
of this review. The signaling pathways leading from DNA
damage to p53 activation have been extensively investi-
gated, and provide intriguing insights into how the activity
of a tumor suppressor can promote lifespan by preventing
cancer and promoting genome maintenance, while para-
doxically reducing lifespan through promotion of cell fate
decisions that can result in tissue degeneration.
The DNA damage responsepathways leading top53
All cells must preserve genome integrity in order to
guarantee proper genetic information propagation follow-
ing division. Single cells respond to genotoxic stress,
including DNA double-strand breaks (DSBs), by activat-
ing a signaling cascade known as the DNA damage
response (DDR). The DDR is a complex interlaced
network comprised of DNA damage repair factors and
cell cycle regulators. Perhaps surprisingly for such an
important mechanism, the DDR preferentially converges
on a single protein, the tumor suppressor p53 (see
Figure 1). While p53 is not the unique regulator and
executor of the DDR, loss of p53 still compromises both
proper repair of lesions and the timely execution of cell
fate decisions.
DNA damage can be caused by a multitude of factors,
but ultimately takes the form of either chemical modiﬁca-
tion to a DNA base, the presence of single-stranded DNA
(ssDNA) or ssDNA break or of a more severe DNA-DSB.
The repair of lesions generated by chemical modiﬁcations
to DNA bases, such as oxidative lesions or bulky adducts,
are rapidly processed by the nucleotide excision repair
(NER) and base excision repair (BER) pathways. For
either BER or NER, it is believed that recruitment of
the ATR/ATRIP (ATM and Rad3-related kinase/ATR-
interacting protein) complex to a ssDNA intermediate in
the repair process promotes initiation of the DDR. The
DDR subsequently entails activation of the checkpoint
kinase CHK1 and ultimately p53 activation (28–30).
When the BER or NER pathways are deﬁcient, the
lesion likely converts into a DNA-DSB and initiates the
DDR by activating the ATM (ataxia telangiectasia
mutated) kinase (31,32) (Figure 1). Replication stress
during S-phase can create ssDNA, which either promotes
ATR activation as described above or progresses to DNA-
DSB (29,30). Examples of replication stress include lesions
that retard or interrupt replication fork progression,
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Figure 1. DNA damage response signaling pathways leading to p53
activation: DNA damage activates PIKK (ATM, ATR and DNA-PK),
which leads to activation of checkpoint kinases (CHK1, CHK2) and
p53. Activated p53 integrates the output of the DDR signaling network
and triggers various cell fate decisions.
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caused by the hyperproliferation induced by certain
oncogenes (25,26).
DNA-DSBs are caused by many stimuli including
ssDNA breaks on opposite DNA strands, replication
fork collapses, high energy radiation or dysfunctional
telomeres, and are dangerous and potentially lethal lesions
(33). DNA-DSBs require prompt repair, which can be
achieved through two independent but not mutually
exclusive mechanisms: error prone non-homologous end-
joining (NHEJ) or relatively error-free homologous
recombination (HR) (33). In response to DNA-DSBs
both ATM and DNA-PK (DNA-dependent protein
kinase) are activated. Activation of DNA-PK can lead
to p53 phosphorylation on serine 15 and 37 (34), but
mostly promotes repair of the DNA-DSB through NHEJ
(28). On the other hand, activation of ATM leads to
direct phosphorylation of p53 on serine 15 and 37 (34), as
well as phosphorylation and activation of another
checkpoint kinase (CHK2), which also phosphorylates
p53 on serine 20 (28,34). It should be noted that while the
pathways described above converge on p53, all three of
the phosphoinositide 3-kinase-related kinases (PIKK)—
ATM, ATR and DNA-PK—as well as the CHK1 and
CHK2 kinases—can phosphorylate a multitude of down-
stream substrates with important functions in DNA repair
and cell cycle arrest (28). One example of this feedback
on repair from the DDR includes the phosphorylation of
the histone variant H2AX at sites of DNA-DSBs by all
three PIKKs. Phosphorylated H2AX (gamma-H2AX) is
essential for stabilizing DNA repair complexes and
promoting eﬃcient repair (35). Nevertheless, p53 remains
a key target of the DDR pathway. DDR-mediated multi-
site p53 phosphorylations reduces binding of the
H/MDM2 (human/mouse double minute 2) ubiquitin
transferase to the p53 molecule, which in turn allows
replacement of ubiquitin moieties by acetylation, resulting
in p53 stabilization and full activation (36). Upon
activation, depending on the severity of the stress signals,
the pattern of post-transcriptional modiﬁcations and the
cellular context, p53 acts as a potent transcriptional
activator or repressor, can translocate to the mitochondria
to induce apoptosis and ﬁnally, can localize directly to
sites of DNA damage and promote proper repair (37–41)
(Figure 1).
p53 activity and ensuingcellular outcomes:to be or notto be
Activation of p53 through the DDR usually leads to either
proper repair of the lesion or elimination of the damaged
cell from the proliferative cell pool. How stringent must
this mechanism be to prevent pathological loss of cells and
how does it impact organ homeostasis? The steps outlined
below are general scenarios, based in some cases on
indirect evidence and in all cases highly dependent on the
cell, tissue and physiological context.
Once a cell has been damaged and the DDR and p53
are activated (Figure 1), a complex signaling network is
engaged to result in a long-term cell fate decision.
In normal mammalian cells, there are four such options.
In all cases, initial processing of the DNA lesions begins
immediately, while activation of cell cycle checkpoints by
CHK1, CHK2 and p53 lead to transient cell growth arrest
(28). While initial processing of the lesions continues,
p53 physically localizes to sites of DNA damage to
promote repair (39) and simultaneously stimulates the
transcription of direct eﬀectors of the cell growth arrest
(e.g. the cyclin-dependent kinase inhibitor p21) as well as
eﬀectors required for eﬃcient DNA repair of complex
lesions that require longer processing (e.g. GADD45) (42).
Once these early steps are in place, there are several
potential cellular outcomes, most of which are heavily
inﬂuenced by the cell type as well as the severity of the
DNA lesions (see also Figure 2).
(i) Transient arrest and proper repair: when DNA
damage is not severe; most of the time the result is proper
repair of the lesions and recovery of the damaged cell with
few, if any, consequences. Clearly this cellular outcome in
which p53 promotes transient arrest and repair, is most
favorable for the cell and organism.
(ii) Defective repair: alternatively, the repair attempt
may fail. If the cell survives and does not arrest growth
permanently (cell fate decisions 3 and 4 below), the result
can be mutations, including chromosomal aberrations.
This scenario, promotes the development of cancer.
(iii) Apoptosis: when the damage is very severe, p53
transcriptionally upregulates eﬀectors of apoptosis such as
proteins of the BH3-only family (PUMA, NOXA and
BAX), and downregulates repressors of apoptosis such as
BCL-2 and SURVIVIN (41). Newly expressed BH3-only
proteins translocate to the mitochondria and promote an
apoptotic cascade starting at the mitochondrial membrane
(43). Moreover, p53 itself can translocate to the mito-
chondria and promote the mitochondrial apoptotic
cascade by interfering directly with anti-apoptotic BCL-2
family members (38). Apoptosis is an important mecha-
nism for eliminating supernumerary cells during embryo-
nic development, and a potent tumor suppressor
mechanism in neonatal and adult organisms. Because
apoptosis irreversibly removes cells from tissues, this cell
fate decision can also deplete tissues of stem or progenitor
cells and contribute to organ degeneration (43).
(iv) Cellular senescence: cellular outcomes following
DNA damage are highly dependent on cell type and
physiological context (42). While lymphoid lineages
usually undergo apoptosis following severe DNA
damage (44), stromal and some epithelial lineages undergo
senescence (45). Senescence is a complex genetic program
and a ﬁnal cell fate decision that establishes permanent cell
growth arrest. The senescence response also causes
dramatic alterations in cellular metabolism including the
secretion of proteins that can modify the tissue micro-
environment (46). In most cell types, activation of p53 is
crucial for initiating the senescence response following
DNA damage. In some cells, p53 is also important for
maintaining the senescence growth arrest. In others, p53
is required only to establish the senescence growth
arrest, which subsequently becomes irreversible and p53-
independent (47). Senescent cells have been shown to
accumulate with age in vivo (10,11,48–50). Because they
have lost the ability to proliferate, senescent cells can no
longer participate in tissue renewal and repair; thus,
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(10,11) cell pools. Moreover, because senescent cells
persist, they have the ability to alter the tissue micro-
environment, and can therefore also promote the degen-
eration of organs and stem cell niches (14,46). Finally,
senescent cells secrete factors such as matrix metallopro-
teinase-3 (MMP-3), which favors extra-cellular matrix
remodeling, promotes defects in epithelial cell diﬀerentia-
tion and stimulates cancer cell growth (46,54,55).
These four cellular outcomes and their potential impact
on tissue homeostasis are summarized in Figure 2 and are
all orchestrated by the p53 signaling network. There is
now little doubt that activation of tumor suppression
mechanisms such as apoptosis and senescence suppress the
development of cancer and therefore promote longevity.
In contrast, loss of p53 leads to a dramatic reduction in
DNA damage-induced cell fate decisions (44,56–60) and
this deﬁcit shortens life span in mice and humans due to
early cancer development (21,22). In light of the cellular
outcome model above, the reasons for this are easily
understood. Defects in p53-dependent cell fate decisions
such as apoptosis and senescence can promote the survival
of cells with potentially severe genotoxic damage, leading
to excessive mutation accumulation and neoplastic trans-
formation (see Figure 2).
While it is clear that reduced p53 activity shortens life
span by promoting cancer, the model above paradoxically
predict that loss of p53 should also prevent permanent cell
fate decisions such as apoptosis and senescence that
promote tissue and organ degeneration (Figure 2).
Moreover, if p53 does promote tissue degeneration
associated with aging, increased p53 activity should
promote aging phenotypes further and do so despite a
reduced incidence of cancer. Some of these possibilities
can and have been tested in mice.
P53 AND AGING IN MOUSE MODELS
Recent studies indicate that proteins involved in DNA
damage repair play an essential role in life span
determination (61–64). Several of these studies implicate
a role of p53 in establishing senescence and implicate it
as a potential regulator of organismal aging (4,6).
Although a physiological role for p53 in aging is
controversial, studies with diﬀerent mouse models indicate
a delicate balance between the tumor suppressive and age-
promoting functions of p53. Here, we discuss several of
these mouse models (summarized in Table 1). Note that
when referring to altered aging phenotypes in mouse
models, in general, premature aging refers to phenotypes
that occur very early (weeks) after birth, whereas
accelarated aging refers to phenotypes that take longer
to develop (months/years), but that would normally take
much longer to develop in control animals.
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Figure 2. The impact of p53-mediated cell fate decisions on tissue homeostasis and organismal longevity: In the presence of severe DNA damage,
eﬀectors triggered by p53 cause transient cell growth arrest, apoptosis or senescence, which in turn promote tissue atrophy and organismal aging.
In contrast, loss of p53 function prevents critical cell fate decisions and dramatically favors cancer.
Table 1. Mouse models that alter p53 activity
Mouse Model Mutation type Aging
phenotype
References
Ku80
/ Ku80 null Enhanced (61,66)
mTR
/ Telomerase null Enhanced (71–73)
Zmpste24
/ Zmpste24 null Enhanced (79)
Brca1
11/11 Hypomorphic mutation Enhanced (84,85)
p53
+/m p53 exon 1-6 plus 23
upstream genes deleted
Enhanced (4,5)
P+/+mice Expression of p53
isoform p44
Enhanced (6)
‘Super–p53’ mouse Extra copy of p53 gene Normal (89–91)
Mdm2
puro/7–12 One null allele and
another hypomorphic
allele
Normal (95)
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Ku80 null mice. Ku80 is a DNA repair protein that
associates with Ku70 to comprise the DNA-binding
component of DNA-PK (65). Ku80 null mice exhibit
accelerated aging phenotypes, including skin atrophy,
osteopenia, hepatocellular degeneration and shortened life
span (61). The authors speculated that a lack of NHEJ
and therefore increased DNA damage load could account
for the accelerated aging phenotype. In support of this
hypothesis, mouse embryo ﬁbroblasts (MEFs) derived
from Ku80
/ mice clearly underwent p53-dependent
premature replicative senescence. A requirement for p53
was illustrated by the limited proliferative capacity of
Ku80
/ cells compared to Ku80
/ p53
+/ ﬁbroblasts
(66). Thus, p53 deﬁciency rescues the premature replica-
tive senescence of Ku80
/ MEFs. If, as suggested,
increased DNA damage and increased p53 activity
is responsible for the accelerated aging phenotype of
Ku80
/ mice, crossing these animals with p53-deﬁcient
mice might rescue the accelerated aging. Interestingly,
mice deﬁcient in both Ku80 and p53 were much more
cancer-prone than mice that were deﬁcient only in p53
(66). The increase in cancer incidence was large enough to
obscure any beneﬁcial eﬀect that loss of p53 might have
conferred on the accelerated aging observed in Ku80-
deﬁcient mice. Clearly, loss of p53 cannot rescue
accelerated aging phenotypes if cancer incidence is
dramatically increased.
Telomerase-deficient mice. Telomerase is a key enzyme
that maintains telomere length in stem cells and other
proliferating cells. Defects in telomerase enzyme compo-
nents lead to telomere dysfunction, resulting in premature
aging phenotypes in mice and dyskeratosis congenita,
which has aspects of premature aging, in humans (67).
Dysfunctional telomeres are recognized by the DNA
repair machinery as DNA-DSBs and thus activate the
DDR and p53 (68–70). Mice deﬁcient in the telomerase
catalytic subunit (Terc) (mTR
/ mice) are prone to
telomere erosion in all tissues, and late generation animals
have a decreased life span and show decreased body
weight, increased skin lesions and delayed wound healing
(71,72). Because mice have long telomeres, early genera-
tion mTR
/ mice are phenotypically normal and have a
normal life span. Importantly, some of the premature
aging phenotypes observed in later generation mTR
/
mice could be rescued by p53 deﬁciency. This result
indicates that, at least in a telomerase-deﬁcient back-
ground, short telomeres activate p53, which contributes to
premature aging (73).
Zmpste24 protease null mice. Zmpste24 is a metallopro-
teinase that participates in the maturation of lamin A.
Lamin A is an essential component of the nuclear
envelope, defects in which can cause premature aging
phenotypes in humans and mice (74–76). Some humans
with progeroid syndromes have been shown to carry
mutations in the genes encoding Lamin A as well as
ZMPSTE24 (77,78). Not surprisingly, mice deﬁcient in
Zmpste24 and lamin A exhibited many features of
premature aging (74–76).
Microarray analysis of transcriptional alterations in
tissues from Zmpste24
/ mice showed an upregulation of
several p53 target genes (79). Although the levels of p53
itself were unchanged, it was proposed that a stress
response triggered by nuclear envelope abnormalities in
Zmpste24
/ mice activated p53. When compared to wild-
type cells, ﬁbroblasts from Zmpste24
/ mice showed a
p53-dependent decrease in proliferative capacity and
premature cellular senescence. Crossing Zmpste24
/
mice to p53
/ mice further tested the possibility that
the progeroid symptoms observed in Zmpste24
/ mice
were due to hyperactive p53. Indeed, loss of p53 in the
Zmpste24
/ background partially rescued the aging
phenotype characteristic of Zmpste24 deﬁciency, mark-
edly increasing body weight and life span. Thus the
premature aging syndrome caused by alterations in
nuclear lamina structure triggers activation of p53,
possibly through increased DNA damage and DDR
signaling (80,81), which contributes to the premature
aging of Zmpste24
/ mice.
BRCA1 hypomorphic mutant mice. BRCA1 is a tumor-
suppressor protein that acts both as a checkpoint protein
and DNA damage repair protein (82). About 98% of
embryos carrying a hypomorphic mutation in Brca1
(BRCA1
11/11) die between days 12 and 18 of gestation.
Importantly, haploid loss of p53 completely suppressed
this embryonic lethality, allowing Brca1
11/11 mice to
survive to adulthood (83). In those adult animals,
Brca1
11/11 p53
+/ females developed tumors whereas
males exhibited accelerated aging phenotypes. These
ﬁndings suggest that genomic instability and DNA
damage due to BRCA1 deﬁciency lead to a rapid cancer
phenotype in females. They also reveal a scenario in which
increased DNA damage in cancer spared males may result
in a remaining hyperactive p53 allele, which could
promote accelerated aging (84). Recent ﬁndings show
that indeed, the ATM-Chk2-p53 DDR pathway is
activated upon BRCA1 deﬁciency in mice (85).
Consistent with an important role for p53 in the DDR,
complete or haploid loss of ATM or Chk2 rescued the
Brca1 deﬁciency-associated embryonic lethality and accel-
erated aging in adult mutant mice. These ﬁndings are
consistent with a model in which BRCA1 deﬁciency
impairs proper DNA damage repair, which in turn
promote p53 hyperactivity through the DDR components
ATM and Chk2 (see Figure 1). In cancer spared animals,
absence of ATM or Chk2 prevents the hyperactivity of
p53 caused by BRCA1 deﬁciency, hence these mice are
rescued from accelerated aging.
Mousemodels that affectp53 directly
Short isoforms of p53 in mice: the p53
+/m mice. The ﬁrst
evidence for a direct role for p53 in promoting aging
phenotypes came from Tyner et al., who generated mice in
which a spontaneous recombination event deleted a
stretch of DNA upstream of the mouse p53 gene
that included exons 1–6 of the p53 coding sequence (4).
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was presumed to be under the transcriptional control of a
promoter from an upstream gene. Experiments with
MEFS isolated from p53
+/m mice indicated that the m
allele product could enhance the stability and the
transacivation activity of p53. Consistent with an increase
in p53 activity, p53
+/m mice were strikingly cancer
resistant at 18 months of age compared to similarly aged
p53
+/+ mice. Surprisingly, however, the cancer resistant
p53
+/m mice had a 20–30% shorter life span. Moreover,
the mutant mice exhibited several signs of accelerated
aging including tissue atrophy (in the skin, skeletal muscle,
liver and lymphoid organs). Thus, enhanced p53 activity
could drive aging phenotypes at the cost of tumor
suppression, at least in these mutant mice. The authors
suggested that the accelerated aging was caused by an
impaired ability of stem cells to produce adequate
numbers of progenitor and mature diﬀerentiated cells.
A recent analysis of hematopoietic stem cell dynamics
in p53
+/m mice conﬁrmed that, compared to wild-type
mice, these mice exhibit a reduced number of proliferating
hematopoietic stem cells with age (5). Haploid insuﬃ-
ciency for p53 (p53
+/) partially rescued the reduced
hematopoietic stem cell proliferative potential, presum-
ably due to diminished p53 activity.
While the phenotypes of p53
+/m mice suggest that
increased p53 activity promotes tumor suppression at the
cost of aging, there are two major caveats to consider.
First, due to the low expression level of the m allele in
p53
+/m tissues, no m-derived protein could be detected.
Second, and more important, the unknown stretch of
DNA upstream of the p53 gene that was deleted in the m
allele has recently been characterized and shown to
include 24 upstream genes in addition to the p53
truncation (86). Absence of one or more of these 24
genes can in principle, give rise to the accelerated aging
and cancer resistance of the p53
+/m mice.
Short isoforms of p53 in mice: the P+ / +
mice. Subsequent studies not only conﬁrmed the idea
that p53 status can modulate organismal aging but
removed some of the ambiguities present in the above
studies (6). Maier et al. created transgenic mice that
overexpressed p44 (a short naturally occurring p53
isoform that lacks the main transactivation domain)
(P+ / + mice). By 4 months of age, P+ / + mice showed
selected signs of premature aging. By 1 year of age, most
of the P+ / + mice had died, whereas the non-transgenic
mice were still alive and healthy. P+ / + mice had a very
low incidence of cancer, suggesting that p44 overexpres-
sion increased wild-type p53 activity. Indeed, the over-
expressed p44 short isoform modulated p53 functions,
resulting in enhanced expression or repression of certain
p53 target genes. Moreover, the authors attributed the
early premature aging phenotypes of p44-tg mice to p53
hyperactivity, which upregulated the activity of the IGF-
signaling pathway. This pathway has been shown to drive
aging in species as diverse as nematodes, fruit ﬂies and
mice (87,88).
The super-p53 mice. In line with phenotypes of p53
+/m
and P+ / + mice, Garcia-Cao et al. showed that transgenic
mice carrying one or two extra copies of wild-type p53
genes (super-p53 or p53 tg mice) were remarkably cancer
resistant. However, and in contrast to p53
+/m and P+ / +
mice, super-p53 mice showed no symptoms of premature
or accelerated aging (89). Notably, cells from super-p53
mice expressed normal basal levels of p53, and displayed
normal levels of p53 activity, in the absence of stress. In
response to DNA damage, however, cells from super-53
mice displayed enhanced p53 activity. Upon whole body
irradiation, super-53 mice showed elevated levels of p21
mRNA in all tissues and increased apoptosis in the
thymus, compared to irradiated control mice. Super-p53
mice were also resistant to carcinogen-induced tumors.
Despite enhanced p53-dependent apoptosis, super-p53
mice had a normal life span and showed no signs of
premature or accelerated aging, as determined by normal
hair growth and skin thickness and an absence of
lordokyphosis and osteoporosis.
Why do these mice with increased p53 activity not show
signs of premature/accelerated aging? The authors spec-
ulate that the constitutively high level of p53 activity in
p53
+/m or P+ / + mice, or a chronic stress signal is
required to chronically activate p53 and induce prema-
ture/accelerated aging. This hypothesis raises the possibi-
lity that enhanced p53-dependent tumor suppression is
possible without accelerating aging or increasing non-
cancer mortality. Conversely, these results also suggest
that super-p53 mice might age prematurely if chronically
stressed. However, the accelerated aging shown by
telomerase-null mice was not further accelerated when
these mice were crossed with super-53 mice (90). The
authors observed that cells harboring DNA damage due
to defective telomeres were more eﬃciently eliminated in
super-p53 mice as compared to wild-type mice, although
p53 did not have any eﬀect on telomere-driven aging.
The authors suggested that the decrease in damaged cells
was not of a suﬃcient magnitude to delay the pathologies
associated with aging in mice. More recently, it was shown
that the double super-p53/p19ARF mice can eﬀec-
tively eliminate cells harboring age-associated persistent
DNA damage markers in the absence of any premature
or accelerated aging phenotypes. In fact, the super-
p53/p19ARF animals were cancer-free, showed increased
resistance to oxidative stress and displayed general signs of
delayed aging (91). The authors suggested that increased,
but properly regulated p53 activity, provide both stress
resistance and tumor suppression activity. It remains to be
seen if super-p53 or super-p53/p19ARF mice display
accelerated aging phenotypes when under other types of
chronic stress.
The hypomorphic Mdm2 mice. H/Mdm2 is a powerful
inhibitor of p53. Mdm2 binds the transcriptional activa-
tion domain of p53 and prevents its interaction with the
transcriptional machinery. Mdm2 also facilitates the
nuclear export of p53, and ubiquitinates p53 and
promotes its degradation by the proteasome (36).
Mdm2-deﬁcient mice are embryonic lethal; deletion of
p53 rescues this lethality, indicating that very high levels of
7480 Nucleic Acids Research, 2007, Vol. 35, No. 22p53 are incompatible with embryonic development
(92,93). Similarly, acute activation of p53 in adult mice
lacking Mdm2 but carrying an inducible p53 protein
was incompatible with survival (94). Mendrysa et al.
generated mice that express low levels of Mdm2
(mdm2
puro/712mice) owing to the presence of one
hypomorphic (puro) and one null allele (7–12). These
mice expressed 30% of the normal level of Mdm2 (95,96).
As expected, these mice also showed increased basal levels
of p53 and, upon activation, increased expression of p53
target genes as well as increased apoptosis in the small
intestine. mdm2
puro/7–12 mice were also highly resistant to
cancer, presumably as a consequence of increased p53
activity. Despite having increased p53 activity, these mice
had a normal life span, and showed no signs of accelerated
aging.
Why do mdm2
puro/7–12 mice escape accelerated aging
despite constitutively high p53 activity? One possibility is
that the p53 activity was not increased to the same extent
in mdm2
puro/7–12 mice as in p53
+/m and P+ / + mice.
Another possibility is that, in p53
+/m and P+ / + mice,
overexpression of an N-terminally truncated p53 causes
p53 activity that is imbalanced or qualitatively altered,
not simply quantitatively altered. Consistent with this
idea, N-terminally truncated forms of p53 can alter the
aﬃnity of full-length p53 for diﬀerent promoters (97).
Thus, a balanced increase in the level of p53 activity and
preservation of p53 speciﬁcity might be required to
enhance tumor suppression without accelerating aging.
As for super-p53 mice, it remains to be seen if
mdm2
puro/7–12 mice display accelerated aging phenotypes
when under stress.
Aging andhuman p53polymorphism at amino acid72
Taken together, the mouse models support the idea that
p53 is a potent tumor suppressor that can, under some
circumstances, also promote aging. Insights into the role
of p53 in aging are also derived from studies of human
populations. Human p53 has a Pro/Arg polymorphism at
amino acid residue 72 (98). Humans carrying one or two
copies of the Pro or Arg p53 form have been studied for
cancer susceptibility, mortality and survival. The results
support a role for p53 in regulating life span in humans.
A recent systematic literature survey done by van
Heemst et al. showed that humans with the Pro/Pro
genotype had a higer risk of developing cancer compared
to the Arg/Arg genotype (99). This ﬁnding agrees with a
previous ﬁnding that p53Arg is a more potent inducer of
apoptosis than the p53Pro form (100,101). A prospective
study done by the same group in 1226 subjects aged 85 or
over showed that the Pro/Pro carriers had a 41%
increased survival, despite a 2.54-fold increase in cancer
mortality, compared to the Arg/Arg carriers (99). The
authors suggested that in older survivors, p53Arg
protected against cancer more eﬃciently than p53Pro
but at the cost of a diminished life span.
In another instance, Orsted et al. studied a large Danish
population of 9219 participants aged 20–95 years for
longevity, survival after cancer diagnosis, and risk of
cancer (102). The authors found that overall 12-year
survival was higher for Pro/Pro carriers compared to Arg/
Arg carriers. Moreover, although Pro/Pro carriers had
the same cancer risk as Arg/Arg carriers, the survival of
Pro/Pro individuals after cancer or a life threatening
disease was higher compared to Arg/Arg individuals. The
authors suggested that the increased longevity of Pro/Pro
individuals after a cancer diagnosis or other life threaten-
ing disease might also be due to an increase in survival.
Again, carriers of a form of p53 that is a less potent
inducer of apoptosis had increased survival after stress,
suggesting that high p53 activity could be detrimental in
humans. While limited in scope, correlations about this
naturally occurring polymorphism and its impact on aging
corroborates to some extent the data obtained from
mouse models described above.
CONCLUSION: FINDING THE RIGHT BALANCE
The tumor suppressor p53 protects the genome by
promoting the repair of potentially carcinogenic lesions
in the DNA, thereby preventing mutations. In addition,
p53 eliminates or arrests the proliferation of damaged or
mutant cells by the processes of apoptosis and cellular
senescence. However, there is mounting evidence that
apoptosis and cellular senescence can lead to aging
phenotypes, possibly by depletion of important stem cell
and other stromal cell pools. Thus, integration of DNA
damage signaling by p53 has been optimized to balance
the beneﬁcial eﬀects of tumor suppression against the
detrimental eﬀects of tissue degeneration. Furthur studies
will help us understand as to how exactly this balance is
achieved and how it also varies among species having
diﬀerent life spans. It remains to be seen whether it will be
possible in humans, as it appears to be possible in mice, to
optimize tumor suppression without accelerating aging.
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